CanaQuest Medical, a clinical-stage, life-sciences company, is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company intends to treat neurological conditions, such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder “PTSD”, including addiction.
CanaQuest’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.
Game Changing Formulations – IP protected, International Patents Filed
- Drug candidate, Rx CQ-001 (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptors allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.
- Drug candidate, Rx CQ-002 (THC molecules + formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.
The Company intends to incorporate Artificial Intelligence (AI) to help diagnose and evaluate mental health at the beginning and through the medication period. By including advanced machine learning algorithms, novel formulation methods, and well-established industry approaches, we are driving the evolution of the mental health industry to improve the lives of millions globally.
CanaQuest has research and clinical trial collaborations with multiple Canadian universities and Institutions and has identified the regulatory pathways for Rx Rx CQ-001 to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions, projected ∼ 3 years.
Team led by Dr. Steven Laviolette, a neuroscientist, with decades of research and pre-clinical trial experience, focused on novel cannabinoid and botanical pharmacotherapies, addressing neurological conditions. Pre-clinical trials completed for Rx CQ-001 and Rx CQ-002. www.laviolettelab.com
University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, Rx CQ-001 and Rx CQ-002, for the treatment of Cannabis Use Disorder “CUD”. https://labo-jutras-aswad.ca/en/laboratory/
Q2 2022 – initiating clinical trial (Phase II, double-blind feasibility trial, 30 patients) to further refine efficacy and dosage of Rx CQ-001 for humans.
Ontario Brain Institute
Q1 2022 – EpLink https://eplink.ca/, the Epilepsy Research Program funded by the Ontario Brain Institute, will conduct a study using rodent models to establish dosing requirements for Rx CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).
Q4 2022 – study results will define dosage of Rx CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.
Hydrx Farms https://hydrx.ca/facilities
Q1 2022 – our Contract Manufacturer, GMP and clinical trial compliance, is completing the SOPs for the Clinical Trial Application process required for the approved and funded clinical trial at the University of Montreal (Cannabis Use Disorder – efficacy, dosage, and safety, 24 patients), for evaluating CanaQuest’s Rx CQ-001 and Rx CQ-002 drug candidates.
Pre-approved and Pending Clinical Trials
The Company is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.
CanaQuest has won Best Medical Cannabis and Botanical Oils Product Development Company, 2022 – North America………awarded by Global Health & Pharma, UK.
Going global by perfecting the science of cannabinoids with the invention of new medical products & improving quality of life.
RESEARCH & DEVELOPMENT COLLABORATIONS
Dr. Laviolette has made two amazing discoveries:
Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) and Drug candidate, Rx CQ-002, supported by (THC molecules + formula) to treat mental disorders.
Western University has performed research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety, and schizophrenia.
Dr. Steven Laviolette, BSc, PhD
Addiction Research Group Dept. of Anatomy & Cell Biology
Dept. of Psychiatry
468 Medical Science Building
The Schulich School of Medicine, University of Western Ontario London, Ontario Canada N6A 5C1
The investigator leading the research is Dr. Steven Laviolette, a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University in London, Ontario. Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status at Western University. Dr. Laviolette’s research team of 13 scientists has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the top tier of neuroscience and psychiatry journals in the world.
Based on successful pre-clinical trial results, CanaQuest has initiated human trials and will seek regulatory approval for RX CQ-001 by applying for a Drug Identification Number “DIN number” with the US-based Food and Drug Administration (FDA) and Health Canada.
Dr. Laviolette stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising epilepsy treatment, which I believe makes the formulation even more promising for these applications.”
The following is a link to Dr. Laviolette’s profile on the Western University website:
Addiction Research Group